Alpha Cubed Investments LLC Sells 153 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Alpha Cubed Investments LLC lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.6% during the fourth quarter, HoldingsChannel reports. The firm owned 5,831 shares of the biopharmaceutical company’s stock after selling 153 shares during the period. Alpha Cubed Investments LLC’s holdings in Gilead Sciences were worth $539,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also bought and sold shares of the company. AE Wealth Management LLC increased its holdings in Gilead Sciences by 11.7% in the 2nd quarter. AE Wealth Management LLC now owns 29,796 shares of the biopharmaceutical company’s stock worth $2,044,000 after acquiring an additional 3,124 shares during the last quarter. Fidelis Capital Partners LLC boosted its position in Gilead Sciences by 39.7% during the second quarter. Fidelis Capital Partners LLC now owns 4,226 shares of the biopharmaceutical company’s stock worth $313,000 after purchasing an additional 1,201 shares during the period. Public Sector Pension Investment Board increased its stake in shares of Gilead Sciences by 72.9% in the second quarter. Public Sector Pension Investment Board now owns 47,722 shares of the biopharmaceutical company’s stock worth $3,274,000 after purchasing an additional 20,120 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Gilead Sciences in the second quarter valued at approximately $8,269,000. Finally, Mill Creek Capital Advisors LLC purchased a new stake in shares of Gilead Sciences during the 2nd quarter valued at approximately $205,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $92.96 on Wednesday. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The stock has a market cap of $115.85 billion, a PE ratio of 1,032.89, a PEG ratio of 1.29 and a beta of 0.18. The company’s fifty day moving average is $91.65 and its 200 day moving average is $84.38. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $98.90.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the prior year, the business posted $2.29 EPS. Research analysts anticipate that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 3.31%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 3,422.22%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of the company’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the transaction, the director now directly owns 8,920 shares in the company, valued at approximately $815,198.80. This represents a 43.21 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the sale, the insider now directly owns 99,599 shares in the company, valued at $9,113,308.50. The trade was a 20.44 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 456,234 shares of company stock worth $42,130,461. 0.29% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on GILD shares. Leerink Partners raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $74.00 to $96.00 in a report on Monday, October 21st. Barclays boosted their price objective on Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a research note on Thursday, November 7th. Royal Bank of Canada restated a “sector perform” rating and issued a $84.00 target price on shares of Gilead Sciences in a research note on Wednesday, December 11th. Truist Financial lifted their target price on Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a report on Friday, November 8th. Finally, Sanford C. Bernstein started coverage on shares of Gilead Sciences in a report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price target on the stock. Eleven analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $97.96.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.